Theodore S Hong1, Jennifer Moughan2, Michael C Garofalo3, Johanna Bendell4, Adam C Berger5, Nicklas B E Oldenburg6, Pramila Rani Anne5, Francisco Perera7, R Jeffrey Lee8, Salma K Jabbour9, Adam Nowlan10, Albert DeNittis11, Christopher Crane12. 1. Massachusetts General Hospital, Boston, Massachusetts. Electronic address: tshong1@mgh.harvard.edu. 2. NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania. 3. University of Maryland School of Medicine, Baltimore, Maryland. 4. Sarah Cannon Research Institute, Nashville, Tennessee. 5. Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. 6. North Main Radiation Oncology, Providence, Rhode Island. 7. London Regional Cancer Program/Western Ontario, London, Ontario. 8. Intermountain Medical Center, Salt Lake City, Utah. 9. Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. 10. Piedmont Hospital, Atlanta, Georgia. 11. Main Line Community Clinical Oncology Program, Wynnewood, Pennsylvania. 12. University of Texas-MD Anderson Cancer Center, Houston, Texas.
Abstract
PURPOSE: To evaluate the rate of gastrointestinal (GI) toxicity of neoadjuvant chemoradiation with capecitabine, oxaliplatin, and intensity modulated radiation therapy (IMRT) in cT3-4 rectal cancer. METHODS AND MATERIALS: Patients with localized, nonmetastatic T3 or T4 rectal cancer <12 cm from the anal verge were enrolled in a prospective, multi-institutional, single-arm study of preoperative chemoradiation. Patients received 45 Gy with IMRT in 25 fractions, followed by a 3-dimensional conformal boost of 5.4 Gy in 3 fractions with concurrent capecitabine/oxaliplatin (CAPOX). Surgery was performed 4 to 8 weeks after the completion of therapy. Patients were recommended to receive FOLFOX chemotherapy after surgery. The primary endpoint of the study was acute grade 2 to 5 GI toxicity. Seventy-one patients provided 80% probability to detect at least a 12% reduction in the specified GI toxicity with the treatment of CAPOX and IMRT, at a significance level of .10 (1-sided). RESULTS: Seventy-nine patients were accrued, of whom 68 were evaluable. Sixty-one patients (89.7%) had cT3 disease, and 37 (54.4%) had cN (+) disease. Postoperative chemotherapy was given to 42 of 68 patients. Fifty-eight patients had target contours drawn per protocol, 5 patients with acceptable variation, and 5 patients with unacceptable variations. Thirty-five patients (51.5%) experienced grade ≥ 2 GI toxicity, 12 patients (17.6%) experienced grade 3 or 4 diarrhea, and pCR was achieved in 10 patients (14.7%). With a median follow-up time of 3.98 years, the 4-year rate of locoregional failure was 7.4% (95% confidence interval [CI]: 1.0%-13.7%). The 4-year rates of OS and DFS were 82.9% (95% CI: 70.1%-90.6%) and 60.6% (95% CI: 47.5%-71.4%), respectively. CONCLUSION: The use of IMRT in neoadjuvant chemoradiation for rectal cancer did not reduce the rate of GI toxicity.
PURPOSE: To evaluate the rate of gastrointestinal (GI) toxicity of neoadjuvant chemoradiation with capecitabine, oxaliplatin, and intensity modulated radiation therapy (IMRT) in cT3-4 rectal cancer. METHODS AND MATERIALS: Patients with localized, nonmetastatic T3 or T4 rectal cancer <12 cm from the anal verge were enrolled in a prospective, multi-institutional, single-arm study of preoperative chemoradiation. Patients received 45 Gy with IMRT in 25 fractions, followed by a 3-dimensional conformal boost of 5.4 Gy in 3 fractions with concurrent capecitabine/oxaliplatin (CAPOX). Surgery was performed 4 to 8 weeks after the completion of therapy. Patients were recommended to receive FOLFOX chemotherapy after surgery. The primary endpoint of the study was acute grade 2 to 5 GI toxicity. Seventy-one patients provided 80% probability to detect at least a 12% reduction in the specified GI toxicity with the treatment of CAPOX and IMRT, at a significance level of .10 (1-sided). RESULTS: Seventy-nine patients were accrued, of whom 68 were evaluable. Sixty-one patients (89.7%) had cT3 disease, and 37 (54.4%) had cN (+) disease. Postoperative chemotherapy was given to 42 of 68 patients. Fifty-eight patients had target contours drawn per protocol, 5 patients with acceptable variation, and 5 patients with unacceptable variations. Thirty-five patients (51.5%) experienced grade ≥ 2 GI toxicity, 12 patients (17.6%) experienced grade 3 or 4 diarrhea, and pCR was achieved in 10 patients (14.7%). With a median follow-up time of 3.98 years, the 4-year rate of locoregional failure was 7.4% (95% confidence interval [CI]: 1.0%-13.7%). The 4-year rates of OS and DFS were 82.9% (95% CI: 70.1%-90.6%) and 60.6% (95% CI: 47.5%-71.4%), respectively. CONCLUSION: The use of IMRT in neoadjuvant chemoradiation for rectal cancer did not reduce the rate of GI toxicity.
Authors: Ronald C Chen; Harvey J Mamon; Marek Ancukiewicz; Joseph H Killoran; Elizabeth M Crowley; Lawrence S Blaszkowsky; Jennifer Y Wo; David P Ryan; Theodore S Hong Journal: Int J Radiat Oncol Biol Phys Date: 2012-03-19 Impact factor: 7.038
Authors: L S Blaszkowsky; D P Ryan; J Szymonifka; D R Borger; A X Zhu; J W Clark; E L Kwak; H J Mamon; J N Allen; E Vasudev; P C Shellito; J C Cusack; D L Berger; T S Hong Journal: Ann Oncol Date: 2014-01 Impact factor: 32.976
Authors: Michael J O'Connell; Linda H Colangelo; Robert W Beart; Nicholas J Petrelli; Carmen J Allegra; Saima Sharif; Henry C Pitot; Anthony F Shields; Jerome C Landry; David P Ryan; David S Parda; Mohammed Mohiuddin; Amit Arora; Lisa S Evans; Nathan Bahary; Gamini S Soori; Janice Eakle; John M Robertson; Dennis F Moore; Michael R Mullane; Benjamin T Marchello; Patrick J Ward; Timothy F Wozniak; Mark S Roh; Greg Yothers; Norman Wolmark Journal: J Clin Oncol Date: 2014-05-05 Impact factor: 44.544
Authors: Kathy L Baglan; Robert C Frazier; Di Yan; Raywin R Huang; Alvaro A Martinez; John M Robertson Journal: Int J Radiat Oncol Biol Phys Date: 2002-01-01 Impact factor: 7.038
Authors: Gary M Freedman; Neal J Meropol; Elin R Sigurdson; John Hoffman; Elaine Callahan; Robert Price; Jonathan Cheng; Steve Cohen; Nancy Lewis; Deborah Watkins-Bruner; André Rogatko; Andre Konski Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-01 Impact factor: 7.038
Authors: Ari Ballonoff; Brian Kavanagh; Martin McCarter; Madeleine Kane; Nathan Pearlman; Russell Nash; Raj J Shah; David Raben; Tracey E Schefter Journal: Am J Clin Oncol Date: 2008-06 Impact factor: 2.339
Authors: M J Gallagher; H D Brereton; R A Rostock; J M Zero; D A Zekoski; L F Poyss; M P Richter; M M Kligerman Journal: Int J Radiat Oncol Biol Phys Date: 1986-09 Impact factor: 7.038
Authors: Babu Zachariah; Clement K Gwede; Jennifer James; Jaffer Ajani; Lisa J Chin; David Donath; Seth A Rosenthal; Brent L Kane; Marvin Rotman; Lawrence Berk; Lisa A Kachnic Journal: J Natl Cancer Inst Date: 2010-03-25 Impact factor: 13.506
Authors: Neil B Newman; Rebecca A Moss; Nell Maloney-Patel; Kristen Donohue; Teresa V Brown; Michael J Nissenblatt; Shou-En Lu; Salma K Jabbour Journal: J Gastrointest Oncol Date: 2017-06
Authors: Noam VanderWalde; Jennifer Moughan; Stuart M Lichtman; Reshma Jagsi; Matthew Ballo; Ari VanderWalde; Mohammed Mohiuddin; Neal J Meropol; Lisa Kachnic; Adam Berger; Jaffer Ajani; Rani Anne; Judith L Hopkins; Amit Arora; Joshua Meyer; Susannah G Ellsworth; R Jeffrey Lee; Nathan Green; Christopher H Crane Journal: J Geriatr Oncol Date: 2021-10-27 Impact factor: 3.599
Authors: Zhifei Sun; Mohamed A Adam; Jina Kim; Brian Czito; Christopher Mantyh; John Migaly Journal: J Gastrointest Surg Date: 2016-08-10 Impact factor: 3.452
Authors: John M David; Gillian Gresham; Salma K Jabbour; Matthew Deek; Shant Thomassian; John M Robertson; Neil B Newman; Joseph M Herman; Arsen Osipov; Peyman Kabolizadeh; Richard Tuli Journal: J Gastrointest Oncol Date: 2018-08